Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Inventiva to Host Analyst and Investor Event on October 8, 2025

  • Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026
  • Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscape

Daix (France), New York City (New York, United States), September 24, 2025 Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company will host an analyst and investor event, providing a strategic corporate update ahead of anticipated Phase 3 topline results for lanifibranor, Inventiva’s lead asset for MASH. The event will be held on Wednesday, Oct. 8, 2025, from 11:30am to 2:00pm ET/5:30pm to 8:00pm CET, in New York City and available live via webcast. 

Agenda topics will include:

  • Lanifibranor’s anticipated positioning in a large global market
  • A deep dive into lanifibranor’s mechanism of action and clinical evidence to date, including key findings from the Phase 2b trial
  • The design and objectives of the ongoing Phase 3 study as well as a progress update and overview of patient baseline characteristics
  • How lanifibranor, driven by its dual intrahepatic and extrahepatic activity, is uniquely suited to address critical unmet needs in MASH.

In addition to presentations from Inventiva’s leadership, the program will feature insights from distinguished key opinion leaders in the MASH field and a patient representative, including: 

  • Nezam Afdhal, MD, Chief of the division of Gastroenterology, Hepatology and Nutrition at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School
  • William Alazawi, MD, Professor of Hepatology and Director of Research at the Queen Mary University of London
  • Henry E. Chang, Executive Director of the Fatty Liver Foundation
  • Arun Sanyal, MD, Director at the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health School of Medicine Internal Medicine Virginia Commonwealth University and co-principal investigator of the Phase 3 NATiV3 study.

Those who would like to participate may register for the live webcast HERE. A webcast replay will be available in the “Investors” section of the Inventiva website at http://www.inventivapharma.com shortly after the conclusion of the event.

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. 
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). http://www.inventivapharma.com

Contacts

Inventiva

Pascaline Clerc
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
    +1 202 499 8937
ICR Healthcare
Alexis Feinberg
Media Relations
inventivapr@icrhealthcare.com
    +1 203 939 2225

 
ICR Healthcare
Patricia L. Bank
Investor Relations

         patti.bank@icrhealthcare.com   
         +1 415 513 1284

Attachment


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.